Thomas Kim currently serves as President and CEO of EpiVario, Inc., a biotechnology company developing neuroepigenetic modulators for trauma-related psychiatric disorders, including therapeutics to prevent relapse in addiction disorders. He is also the President and CEO of ReEngage Therapeutics, an emerging biotech company focused on metabolism and its role in aging, developing novel treatments for longevity disorders including cancer and neurodegeneration.

Mr. Kim holds several advisory positions. He is a member of the External Advisory Board to the President of the College of Science at Georgia Institute of Technology. Mr. Kim also serves on the Board of Directors for the TANGO2 Research Foundation, where he provides support and critical decision-making to drive the foundation’s mission of finding a cure for TANGO2 related diseases.

Mr. Kim’s extensive experience as a biotech executive and corporate attorney, including past roles as General Counsel at INOVIO Pharmaceuticals and Corporate Counsel at DuPont, has equipped him with a unique blend of legal, business, and scientific expertise. This diverse experience enables him to effectively lead innovative biotech companies and contribute to advancing the field of life sciences.